SPONSOR
Swiss Cancer Institute
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: Metastatic Castration-resistant Prostate CancerRecurrent Prostate CancerMetastatic NSCLC - Non-Small Cell Lung Cancer
Swiss Cancer Institute is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Metastatic Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Metastatic NSCLC - Non-Small Cell Lung Cancer.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Swiss Cancer Institute
How many clinical trials has Swiss Cancer Institute sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Swiss Cancer Institute, of which 3 are actively recruiting participants. These trials cover conditions including Metastatic Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Metastatic NSCLC - Non-Small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Swiss Cancer Institute research focus on?
Swiss Cancer Institute clinical trials span Metastatic Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Metastatic NSCLC - Non-Small Cell Lung Cancer. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Swiss Cancer Institute clinical trial?
To participate in a Swiss Cancer Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Swiss Cancer Institute trials with current recruitment status updated daily.
Clinical Trials by Swiss Cancer Institute
NCT06401980 Phase 2
Recruiting
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
NCT07365423 Phase 2
Recruiting
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
Recurrent Prostate Cancer
NCT07020065 Phase 2
Recruiting
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Metastatic NSCLC - Non-Small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology